| Japanese |
|---|
| Title | バセドウ病の131I治療後の甲状線機能の経時的推移 - 晩発性甲状腺機能低下症の指標の検討 - |
|---|
| Subtitle | 原著 |
|---|
| Authors | 日下部きよ子*, 中野敬子*, 太田淑子*, 牧正子*, 廣江道昭*, 重田帝子*, 小池幸子**, 栗原重子**, 出村黎子**, 出村博** |
|---|
| Authors(kana) | |
|---|
| Organization | *東京女子医科大学放射線医学教室, **ラジオアッセイ科 |
|---|
| Journal | 核医学 |
|---|
| Volume | 27 |
|---|
| Number | 4 |
|---|
| Page | 333-340 |
|---|
| Year/Month | 1990/4 |
|---|
| Article | 原著 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「要旨」 バセドウ病の131I治療後, 晩発性甲状腺機能低下症に至った症例と正常機能を保っている例について, 長期の甲状腺機能の経時的推移を観察した. 131I治療後10年まで甲状腺治療を必要としなかった33例を正常群, 晩発性機能低下症のために甲状腺ホルモンの補充療法を必要とした11例を低下群とした. 両群とも, 1回の131I投与で甲状腺機能の正常化を目的として治療した症例で, 年齢, 甲状腺腫の大きさ, 131I 24時間摂取率, 治療前の血清T4値, T3摂取率, 131I治療量に差はなかった. 正常群の28.6%, 低下群の66.7%に131I治療後4か月で一過性甲状腺機能低下症が生じた. 正常群では6か月でT3値が正常範囲より高値にまで回復したが, 低下群では70%の症例が未だ正常範囲に止まった. 6か月のT3摂取率が未だ正常範囲より低い値の症例では晩発性機能低下症になる例が多かった. しかし低下群と正常群との間にfollow-up studyの経過に明らかな差は見られなかった. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | Graves' disease, 131I therapy, Lateonset hypothyroidism, Subclinical hypothyroidism |
|---|
| English |
|---|
| Title | Long-term Follow-up Study of I-131 Therapy for Graves' Disease - Index Associated with Late-onset Hypothyroidism - |
|---|
| Subtitle | Original Articles |
|---|
| Authors | Kiyoko KUSAKABE*, Keiko NAKANO*, Masako MAKI*, Yoshiko OHTA*, Michiaki HIROE*, Akiko SHIGETA*, Shigeko KURIHARA**, Sachiko KOIKE**, Reiko DEMURA**, Hiroshi DEMURA** |
|---|
| Authors(kana) | |
|---|
| Organization | *Department of Radiology, **Department of Radioassay, Tokyo Women's Medical College |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 27 |
|---|
| Number | 4 |
|---|
| Page | 333-340 |
|---|
| Year/Month | 1990/4 |
|---|
| Article | Original article |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | [Summary] We have studied the follow-up of thyroid function in the patients with late-onset hypothyroidism and euthyroidism after I-131 therapy of hyperthyroidism. Thirty three patients who did not need the thyroid treatment until ten years after I-131 therapy were classified as euthyroid group. And eleven patients who needed the thyroid supplement of thyroid hormone for late-onset hypothyroidism were classified as hypothyroid group. Patients in both groups who required only a single dose of I-131 for successful treatment of hyperthyroidism had similer age, gland size, 24 hour I-131 uptake, pretreatment serum T3 uptake level and T4 concentration, and I-131 treatment dose. Subclinical hypothyroidism occured in 28.6% of euthyroid group and 66.7% of hypothyroid group four months after I-131 therapy. The levels of T3 were recovered to higher than normal range at 6 months in euthyroid group, while the levels of T3 were kept within the normal range in the seventy percent of hypothyroid group. Patients who were still lower in the level of T3 uptake than normal range at 6 months had a higher incidence of lateonset hypothyroidism. Our observation showed no significant difference in the course of follow-up studies after I-131 therapy between the patients with late-onset hypothyroidism and euthyroidism. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | Graves' disease, 131I therapy, Lateonset hypothyroidism, Subclinical hypothyroidism |
|---|